|

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

RECRUITINGSponsored by University of Chicago
Actively Recruiting
SponsorUniversity of Chicago
Started2022-04-18
Est. completion2027-03-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05264051

Summary

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated

Exclusion Criteria:

* \<18 yrs. of age

Conditions2

Liver DiseaseLiver Diseases

Locations1 site

The University of Chicago
Chicago, Illinois, 60637
Maria Newsome773-702-2788mnewsome1@bsd.uchicago.edu

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.